CORONA Remedies Limited (CORONA) — Announcement | 30 June 2026(2 announcements)

· NSE Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
1 Announcement Neutral 📄 PDF

CORONA Remedies announced the commercial start of operations at its EU-GMP approved women's hormone manufacturing facility in Ahmedabad, marking a key expansion in its pharma capabilities. The new plant, spanning 100,000 sq. ft., has an annual capacity of 194 million tablets/capsules and 1.5 million ointments/gels, boosting in-house hormone production by nearly 20%. The facility uses advanced closed-loop systems and real-time monitoring to ensure quality. This development strengthens the company's position in the growing women's healthcare market and supports both domestic and international demand for specialized hormone therapies.

2 Announcement Neutral 📄 PDF

CORONA Remedies announced the commercial launch of its EU-GMP approved women's hormone manufacturing facility in Ahmedabad, marking a major expansion in specialized pharma capacity. The new 1.0 lakh sq. ft. plant boosts in-house hormone production by nearly 20% with advanced closed-loop systems and a capacity of 194 million tablets/capsules annually. This facility strengthens India's pharma ecosystem and supports growing demand for hormonal therapies, particularly in fertility and menopause management.

About CORONA Remedies Limited (CORONA)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹10,869.98 Cr

View full CORONA stock details →

📡 Get AI alerts when CORONA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track CORONA — Free

📊 More CORONA filings

See all CORONA filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when CORONA files new disclosures

Track CORONA filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track CORONA — Free

Free account · 2 AI queries/day